Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Post a job

Symposium

[Free Online Symposium] Oxbryta® (Voxelotor) tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned (jointly by PBSS and CLSA)


Speakers: Mira Pochron PhD (Head of Translational Biology, Global Blood Therapeutics)
Organizers: Dennis Hu, Cyrus Khojasteh and Dewakar Sangaraju (all of Genentech)
Date: 2021-02-16
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (1)CLS
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-02-15  (it will close sooner if the seating cap is reached)

About the Topic

Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat

the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.


This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).


About the Speakers

Mira Pochron, PhD

Staff Scientist, Head of Translational Biology

Global Blood Therapeutics, Inc

Dr. Mira Pochron currently serves as the Head of Translational Biology at Global Blood Therapeutics (GBT). During her tenure at GBT she was an integral part of developing and overseeing the collection of pharmacodynamic data in the phase 1/2a studies with voxelotor and continues to oversee the collection of pharmacodynamic and biomarker data. She has been with GBT since it’s early days in 2011 and been a core team member involved in assay development, compound screening and animal studies with Hb modifiers, such as voxelotor. Dr. Pochron received her Ph.D. in Chemistry and Biochemistry from University of California, Santa Cruz.


2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-08-14, [Free Online] Advances in Cancer Therapeutics
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projections for Antibodies and Novel Therapeutic Modalities: Antibodies, ADCs, Covalent Inhibitors, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
┬ęPharmaceutical & BioScience Society, International; Last Modified: 6/15/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Simulations Plus Join us for MIDD+ San Francisco, a free event June 6-7. Hear scientific presentations from industry leaders, train with experts & connect with peers.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Submit a Text Ad